Physician profile
Robert Joseph Parkes
NPI 1235189663
$3,575.78
in general payments reported to CMS, 2019-2025
25 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $317 · 2021: $331 · 2022: $569 · 2023: $304 · 2024: $445 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $494.18 | 2019-2025 | |
| Abbott Laboratories | $321.40 | 2019-2022 | |
| Boston Scientific Corporation | $305.76 | 2021-2025 | Ranger, Watchman Flx, Ekosonic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.03 | 2019-2023 | Jardiance |
| Abiomed | $259.99 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.57 | 2019-2025 | Lifevest |
| Chiesi USA, INC. | $232.25 | 2019-2023 | Cleviprex, Kengreal |
| Medtronic, INC. | $185.82 | 2021-2025 | Corevalve Evolut R, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $182.65 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $162.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $160.54 | 2019-2023 | Farxiga |
| Inari Medical, INC. | $142.74 | 2019 | |
| Amgen INC. | $132.06 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $124.03 | 2019-2020 | |
| Terumo Medical Corporation | $59.34 | 2022-2025 | Angio-Seal, Metacross Otw, Azur Cx Detachable |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.72 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.76 | 2019-2023 | Camzyos |
| Biosense Webster, INC. | $29.54 | 2023 | Carto 3 |
| Sanara Medtech INC. | $27.83 | 2025 | Celleraterx |
| Sanofi-Aventis U.S. LLC | $27.60 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $18.61 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.89 | 2023 | Inpefa |
| Novo Nordisk INC | $15.91 | 2023 | |
| Bridgebio Pharma, INC. | $13.89 | 2025 | Attruby |
| Philips North America LLC | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Parkes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.